Zahrat Al Rawdah, a wholly-owned subsidiary of Julphar, operates 173 pharmacy outlets across Saudi Arabia
The company registered double-digit growth in the UAE and GCC region markets due to continued positive developments in key markets including Saudi Arabia
Basel Ziyadeh will succeed Dr Essam Mohamed, who stepped down from the role, having joined in 2020
Year to date, the company has launched 25 new products and is set to deliver its full-year 2022 objectives
The partnerships will play a significant role in boosting economic development through the National ICV Program
Julphar recently announced its 2030 growth strategy
Julphar will expand its presence into new territories, including CIS countries, Turkey, Latin America and Africa, to create new revenue streams
The pharma company announced it had seen top line growth and a return to a profitable bottom line compared to the previous year
The acquisition comes as part of efforts to boost Yas Holding’s healthcare manufacturing and distribution ecosystem
Julphar has inked a deal with G42 Medications Trading
The company has announced a net loss of Dhs25.6m for Q2 2020
The new capital is also expected to help it expand operations in key markets in the region
The kingdom banned Julphar’s products in September 2018 for failing to meet regional standards
Under the deal, EMD Millipore will sell recombinant human insulin manufactured by UAE-based pharmaceutical firm Julphar.
The pharmaceutical company has seen a profit rise of 5.6 per cent for the first half of last year, with operating profit also up.